Herpes simplex virus 1 tegument protein US11 downmodulates the RLR signaling pathway via direct interaction with RIG-I and MDA-5ICP0 prevents RNase L-independent rRNA cleavage in herpes simplex virus type 1-infected cellsInnate cellular response to virus particle entry requires IRF3 but not virus replicationThe herpes simplex virus ICP0 RING finger domain inhibits IRF3- and IRF7-mediated activation of interferon-stimulated genesReplication of subgenomic hepatitis C virus replicons in mouse fibroblasts is facilitated by deletion of interferon regulatory factor 3 and expression of liver-specific microRNA 122Distinct functional motifs within the IL-17 receptor regulate signal transduction and target gene expressionFunctional inaccessibility of quiescent herpes simplex virus genomesThe Importance of Physiologically Relevant Cell Lines for Studying Virus-Host InteractionsAnalysis of anti-interferon properties of the herpes simplex virus type I ICP0 proteinThe nitric oxide pathway provides innate antiviral protection in conjunction with the type I interferon pathway in fibroblastsVaricella-zoster virus immediate-early protein ORF61 abrogates the IRF3-mediated innate immune response through degradation of activated IRF3Treating viral exacerbations of chronic obstructive pulmonary disease: insights from a mouse model of cigarette smoke and H1N1 influenza infectionThe role of palmitoylation for protein recruitment to the inner membrane complex of the malaria parasiteFimH adhesin of type 1 fimbriae is a potent inducer of innate antimicrobial responses which requires TLR4 and type 1 interferon signalling.An accessory to the 'Trinity': SR-As are essential pathogen sensors of extracellular dsRNA, mediating entry and leading to subsequent type I IFN responses.Cellular localization of the herpes simplex virus ICP0 protein dictates its ability to block IRF3-mediated innate immune responsesPermissiveness of human cancer cells to oncolytic bovine herpesvirus 1 is mediated in part by KRAS activityNovel roles of cytoplasmic ICP0: proteasome-independent functions of the RING finger are required to block interferon-stimulated gene production but not to promote viral replication.Long double-stranded RNA induces an antiviral response independent of IFN regulatory factor 3, IFN-beta promoter stimulator 1, and IFNType-I interferon signaling through ISGF3 complex is required for sustained Rip3 activation and necroptosis in macrophages.Recognition of virus infection and innate host responses to viral gene therapy vectors.Anti-NMDA receptor encephalitis. The disorder, the diagnosis and the immunobiology.Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapyThe herpes simplex virus 1-encoded envelope glycoprotein B activates NF-κB through the Toll-like receptor 2 and MyD88/TRAF6-dependent signaling pathway.Activation and inhibition of virus and interferon: the herpesvirus story.Induction of innate immunity against herpes simplex virus type 2 infection via local delivery of Toll-like receptor ligands correlates with beta interferon production.Handling of the cotton rat in studies for the pre-clinical evaluation of oncolytic viruses.Innate and adaptive immune responses to herpes simplex virusHerpesviruses and the innate immune response.Comparative functional evaluation of immunocompetent mouse breast cancer models established from PyMT-tumors using small animal PET with [(18)F]FDG and [(18)F]FLTMARCO is required for TLR2- and Nod2-mediated responses to Streptococcus pneumoniae and clearance of pneumococcal colonization in the murine nasopharynx.Membrane Perturbation-Associated Ca2+ Signaling and Incoming Genome Sensing Are Required for the Host Response to Low-Level Enveloped Virus Particle EntryMechanisms employed by herpes simplex virus 1 to inhibit the interferon response.Recent advances in understanding viral evasion of type I interferon.Novel paradigms of innate immune sensing of viral infections.Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategiesExtracellular dsRNA: its function and mechanism of cellular uptake.Danger, diversity and priming in innate antiviral immunity.The role of oncolytic virus immunotherapies to subvert cancer immune evasion.Oncolytic bovine herpesvirus type 1 as a broad spectrum cancer therapeutic.
P50
Q24304261-81C0D71D-DC0D-4648-9738-709C5A4DC07DQ24535541-95B27561-249D-478C-8407-8B78271C1564Q24607212-2666692D-22BA-448E-9B35-E4FA15472B57Q24607496-90D91F40-E663-4674-BF69-5DD011C78423Q24611792-5DBD1A89-652E-468D-A5DB-B912A8A423E4Q24674584-B48FB354-DA73-41F3-95AF-E723D461B7DFQ24815909-A085CF29-09DE-4067-AB60-E38402F85948Q28079490-7DB2D6B6-A441-4734-B303-F9992773421FQ28260264-DEC56CF0-8EF2-4CCE-B5FA-A2C5DBBC5532Q28481008-F1619139-C2A6-4FA5-A87A-12354EAB635DQ28743826-BE28431D-BB84-404A-BBC2-FB0476B05C8FQ28748904-402385C6-7E2C-48C5-A888-A68262F544CEQ30039084-27CFA793-019E-4BB1-A26A-49D85D814A63Q33389846-C6E41F48-9696-4F4E-B1A7-F17518027094Q33548730-BF287E03-16BA-41B4-8106-C0416753878DQ33573566-96FE3E22-8882-4DC8-A4EF-59B08C0ADA41Q33743847-BC0C0E06-66AF-4C65-9884-5F415EF70431Q33900347-7BD83306-14AF-4637-A092-78A8E0CA0D9CQ33911630-45FA65EF-13AD-4B03-8169-5541E7A3E3F7Q34025307-93746059-00AA-4067-82B8-573623A8BAE0Q34080884-B465FF5D-2940-4BBD-9179-7783A83650F8Q34263031-38AB9AE1-9615-45CA-8168-1F3629500867Q34556927-F13C5549-1727-490C-96FC-2914B47A7F9CQ34575498-D8CB7E84-4569-409A-8485-2D930771A837Q34600005-11A0EDD9-CC51-4BD2-9E05-87F9B1CA5BBCQ35101507-B9637650-3C64-4BB4-A111-C705008C742EQ35161325-3B77AF71-3A80-4159-938F-8620363EF795Q35260078-17871282-F52E-4676-9A87-1D32EA2261FFQ36202957-C6EE39A7-FB9B-4028-BCC5-5D0A76EB9C96Q36338316-50E72BB1-E327-4691-93ED-FC0D2029F7E9Q36487485-6442BD5B-D890-4296-B718-C67F7C67B502Q36736620-0C2BF98C-6AC4-4896-8C0C-91132DE7ED99Q37582942-5E17494E-03EC-4552-B30B-5A0190307011Q38061716-553390CD-298A-46CE-87F3-60DC4B7E294EQ38117032-CD518C3E-3A28-4B1D-867A-98A87E2D512EQ38139255-CAF50277-13D0-43DC-B92B-BC5548EBC4C6Q38218187-C10C55D3-5D3A-4C80-B11D-E5BF288FCABBQ38235760-7E17E2F9-8AA6-446A-AD5D-167717F4413EQ38357137-BF6D6CE6-ABF9-4994-B425-5881B3BCA214Q38408111-249D3D62-2742-4477-879D-39678250B42A
P50
description
Canadees virologe
@nl
Canadian virologist
@en
Canadian virologist
@en-ca
Canadian virologist
@en-gb
viróloga canadiense
@es
عالمة فيروسات كندية
@ar
name
Karen L Mossman
@en
Karen L Mossman
@nl
Karen L Mossman
@sl
type
label
Karen L Mossman
@en
Karen L Mossman
@nl
Karen L Mossman
@sl
altLabel
Karen Louise Mossman
@en
Karen Mossman
@en
prefLabel
Karen L Mossman
@en
Karen L Mossman
@nl
Karen L Mossman
@sl
P214
P106
P1960
258dXW0AAAAJ
P21
P214
P27
P31
P496
0000-0002-1725-5873
P7859
lccn-nb2011023352